Completed PHASE4 INTERVENTIONAL 1-arm NCT00564772

Raltegravir Kaletra Pharmacokinetics (RAL-KAL)

An Open-Label, Sequential, 3-Period Study to Evaluate Pharmacokinetics of Coadministered Raltegravir (Isentress) and Lopinavir-Ritonavir (Kaletra) in Healthy Adults

Sponsor: Allina Health System

Conditions Healthy

Interventions Raltegravir, lopinavir, ritonavir

Updated 6 times since 2017 Last updated: Mar 19, 2019 Started: Nov 30, 2007 Primary completion: Dec 31, 2007 Completion: Dec 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Healthy, this trial is completed. The trial is conducted by Allina Health System and has accumulated 6 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Apr 2019 — Jan 2021 [monthly]

Completed PHASE4
Jun 2018 — Apr 2019 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Nov 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Allina Health System

Data source: Allina Health System

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Saint Paul, United States